Journal of Neuroimmune Pharmacology

, Volume 4, Issue 3, pp 317–327 | Cite as

4-Aminopyridine Improves Spatial Memory in a Murine Model of HIV-1 Encephalitis

  • James P. Keblesh
  • Huanyu Dou
  • Howard E. Gendelman
  • Huangui Xiong
Original Article

Abstract

HIV-1-associated neurocognitive disorders (HAND) remains a significant source of morbidity in the era of wide spread use of highly active antiretroviral therapy. Disease is precipitated by low levels of viral growth and glial immune activation within the central nervous system. Blood borne macrophage and microglia affect a proinflammatory response and release viral proteins that affects neuronal viability and leads to death of nerve cells. Increasing evidence supports the notion that HAND is functional channelopathy, but proof of this concept remains incomplete. Based on their role in learning and memory processes, we now posit that voltage-gated potassium (Kv) channels could be a functional substrate for disease. This was tested in the severe combined immunodeficient (SCID) mouse model of HIV-1 encephalitis (HIVE) by examining whether the Kv channel blocker, 4-aminopyridine (4-AP), could affect behavioral, electrophysiological, and morphological measures of learning and memory. HIVE SCID mice showed impaired spatial memory in radial arm water maze tests. Electrophysiology studies revealed a reduction of long-term potentiation (LTP) in the CA1 region of the hippocampus. Importantly, systemic administration of 4-AP blocked HIV-1-associated reduction of LTP and improved animal performance in the radial arm water maze. These results support the importance of Kv channel dysfunction in disease but, more importantly, provide a potential target for adjunctive therapies for HAND.

Keywords

voltage-gated K+ channels 4-aminopyridine hippocampal slice EPSP learning and memory HIV-1 encephalitis 

References

  1. Adle-Biassette H, Levy Y, Colombel M, Poron F, Natchev S, Keohane C, Gray F (1995) Neuronal apoptosis in HIV infection in adults. Neuropathol Appl Neurobiol 21:218–227. doi:10.1111/j.1365-2990.1995.tb01053.x PubMedCrossRefGoogle Scholar
  2. Anderson ER, Boyle J, Zink WE, Persidsky Y, Gendelman HE, Xiong H (2003) Hippocampal synaptic dysfunction in a murine model of human immunodeficiency virus type 1 encephalitis. Neuroscience 118:359–369. doi:10.1016/S0306-4522(02)00925-9 PubMedCrossRefGoogle Scholar
  3. Anderson ER, Gendelman HE, Xiong H (2004) Memantine protects hippocampal neuronal function in murine human immunodeficiency virus type 1 encephalitis. J Neurosci 24:7194–7198. doi:10.1523/JNEUROSCI.1933-04.2004 PubMedCrossRefGoogle Scholar
  4. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789–1799. doi:10.1212/01.WNL.0000287431.88658.8b PubMedCrossRefGoogle Scholar
  5. Avgeropoulos N, Kelley B, Middaugh L, Arrigo S, Persidsky Y, Gendelman HE, Tyor WR (1998) SCID mice with HIV encephalitis develop behavioral abnormalities. J Acquir Immune Defic Syndr Hum Retrovirol 18:13–20PubMedGoogle Scholar
  6. Beeton C, Barbaria J, Giraud P, Devaux J, Benoliel AM, Gola M, Sabatier JM, Bernard D, Crest M, Beraud E (2001) Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J Immunol 166:936–944PubMedGoogle Scholar
  7. Bever CT Jr (1994) The current status of studies of aminopyridines in patients with multiple sclerosis. Ann Neurol 36(Suppl):S118–S121. doi:10.1002/ana.410360728 PubMedCrossRefGoogle Scholar
  8. Bever CT Jr, Young D, Anderson PA, Krumholz A, Conway K, Leslie J, Eddington N, Plaisance KI, Panitch HS, Dhib-Jalbut S et al (1994) The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 44:1054–1059PubMedGoogle Scholar
  9. Blunck R, Scheel O, Muller M, Brandenburg K, Seitzer U, Seydel U (2001) New insights into endotoxin-induced activation of macrophages: involvement of a K+ channel in transmembrane signaling. J Immunol 166:1009–1015PubMedGoogle Scholar
  10. Bouwman FH, Skolasky RL, Hes D, Selnes OA, Glass JD, Nance-Sproson TE, Royal W, Dal Pan GJ, McArthur JC (1998) Variable progression of HIV-associated dementia. Neurology 50:1814–1820PubMedGoogle Scholar
  11. Davis FA, Stefoski D, Rush J (1990) Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 27:186–192. doi:10.1002/ana.410270215 PubMedCrossRefGoogle Scholar
  12. Ellis RJ, Deutsch R, Heaton RK, Marcotte TD, McCutchan JA, Nelson JA, Abramson I, Thal LJ, Atkinson JH, Wallace MR, Grant I (1997) Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch Neurol 54:416–424PubMedGoogle Scholar
  13. Everall IP, Heaton RK, Marcotte TD, Ellis RJ, McCutchan JA, Atkinson JH, Grant I, Mallory M, Masliah E (1999) Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center. Brain Pathol 9:209–217PubMedGoogle Scholar
  14. Fox L, Alford M, Achim C, Mallory M, Masliah E (1997) Neurodegeneration of somatostatin-immunoreactive neurons in HIV encephalitis. J Neuropathol Exp Neurol 56:360–368. doi:10.1097/00005072-199704000-00004 PubMedCrossRefGoogle Scholar
  15. Gallin EK (1991) Ion channels in leukocytes. Physiol Rev 71:775–811PubMedGoogle Scholar
  16. Gelbard HA, James HJ, Sharer LR, Perry SW, Saito Y, Kazee AM, Blumberg BM, Epstein LG (1995) Apoptotic neurons in brains from paediatric patients with HIV-1 encephalitis and progressive encephalopathy. Neuropathol Appl Neurobiol 21:208–217. doi:10.1111/j.1365-2990.1995.tb01052.x PubMedCrossRefGoogle Scholar
  17. Gelman BB, Soukup VM, Schuenke KW, Keherly MJ, Holzer C 3rd, Richey FJ, Lahart CJ (2004) Acquired neuronal channelopathies in HIV-associated dementia. J Neuroimmunol 157:111–119. doi:10.1016/j.jneuroim.2004.08.044 PubMedCrossRefGoogle Scholar
  18. Gendelman HE, Zheng J, Coulter CL, Ghorpade A, Che M, Thylin M, Rubocki R, Persidsky Y, Hahn F, Reinhard J Jr, Swindells S (1998) Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia. J Infect Dis 178:1000–1007. doi:10.1086/515693 PubMedCrossRefGoogle Scholar
  19. Ghelardini C, Galeotti N, Bartolini A (1998) Influence of potassium channel modulators on cognitive processes in mice. Br J Pharmacol 123:1079–1084. doi:10.1038/sj.bjp.0701709 PubMedCrossRefGoogle Scholar
  20. Giese KP, Storm JF, Reuter D, Fedorov NB, Shao LR, Leicher T, Pongs O, Silva AJ (1998) Reduced K+ channel inactivation, spike broadening, and after-hyperpolarization in Kvbeta1.1-deficient mice with impaired learning. Learn Mem 5:257–273PubMedGoogle Scholar
  21. Giese KP, Peters M, Vernon J (2001) Modulation of excitability as a learning and memory mechanism: a molecular genetic perspective. Physiol Behav 73:803–810. doi:10.1016/S0031-9384(01)00517-0 PubMedCrossRefGoogle Scholar
  22. Glass JD, Wesselingh SL, Selnes OA, McArthur JC (1993) Clinical neuropathologic correlation in HIV-associated dementia. Neurology 43:2230–2237PubMedGoogle Scholar
  23. Glass JD, Fedor H, Wesselingh SL, McArthur JC (1995) Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 38:755–762. doi:10.1002/ana.410380510 PubMedCrossRefGoogle Scholar
  24. Gonzalez-Scarano F, Martin-Garcia J (2005) The neuropathogenesis of AIDS. Nat Rev Immunol 5:69–81. doi:10.1038/nri1527 PubMedCrossRefGoogle Scholar
  25. Haslberger A, Romanin C, Koerber R (1992) Membrane potential modulates release of tumor necrosis factor in lipopolysaccharide-stimulated mouse macrophages. Mol Biol Cell 3:451–460PubMedGoogle Scholar
  26. Hu D, Liu J, Xiong H (2007) Macrophage activates delayed-rectifier type K+ channels in cultured rat hippocampal neurons. The 37th Annual Meeting of the Society for Neuroscience, Nov 3 to 7, San Diego, CaliforniaGoogle Scholar
  27. Irvine E, Keblesh J, Liu J, Xiong H (2007) Voltage-gated potassium channel modulation of neurotoxic activity in human immunodeficiency virus type-1(HIV-1)-infected macrophages. J Neuroimmune Pharmacol 2:265–269. doi:10.1007/s11481-007-9072-4 PubMedCrossRefGoogle Scholar
  28. Kandanearatchi A, Williams B, Everall IP (2003) Assessing the efficacy of highly active antiretroviral therapy in the brain. Brain Pathol 13:104–110PubMedGoogle Scholar
  29. Kaul M, Garden GA, Lipton SA (2001) Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410:988–994. doi:10.1038/35073667 PubMedCrossRefGoogle Scholar
  30. Langford TD, Letendre SL, Larrea GJ, Masliah E (2003) Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol 13:195–210PubMedGoogle Scholar
  31. Lisman JE, Harris KM (1993) Quantal analysis and synaptic anatomy—integrating two views of hippocampal plasticity. Trends Neurosci 16:141–147. doi:10.1016/0166-2236(93)90122-3 PubMedCrossRefGoogle Scholar
  32. Mackenzie AB, Chirakkal H, North RA (2003) Kv1.3 potassium channels in human alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 285:L862–L868PubMedGoogle Scholar
  33. Malenka RC, Bear MF (2004) LTP and LTD: an embarrassment of riches. Neuron 44:5–21. doi:10.1016/j.neuron.2004.09.012 PubMedCrossRefGoogle Scholar
  34. Maruyama N, Kakuta Y, Yamauchi K, Ohkawara Y, Aizawa T, Ohrui T, Nara M, Oshiro T, Ohno I, Tamura G et al (1994) Quinine inhibits production of tumor necrosis factor-alpha from human alveolar macrophages. Am J Respir Cell Mol Biol 10:514–520PubMedGoogle Scholar
  35. Masliah E, Ge N, Achim C, Hansen L, Wiley C (1992) Selective neuronal vulnerability in HIV encephalitis. J Neuropathol Exp Neurol 51:585–593. doi:10.1097/00005072-199211000-00003 PubMedCrossRefGoogle Scholar
  36. Masliah E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, Mallory M, Achim CL, McCutchan JA, Nelson JA, Atkinson JH, Grant I (1997) Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol 42:963–972. doi:10.1002/ana.410420618 PubMedCrossRefGoogle Scholar
  37. McArthur JC, Haughey N, Gartner S, Conant K, Pardo C, Nath A, Sacktor N (2003) Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol 9:205–221. doi:10.1080/713831484 PubMedCrossRefGoogle Scholar
  38. McArthur JC, Brew BJ, Nath A (2005) Neurological complications of HIV infection. Lancet Neurol 4:543–555. doi:10.1016/S1474-4422(05)70165-4 PubMedCrossRefGoogle Scholar
  39. McCutchan JA, Wu JW, Robertson K, Koletar SL, Ellis RJ, Cohn S, Taylor M, Woods S, Heaton R, Currier J, Williams PL (2007) HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. AIDS 21:1109–1117. doi:10.1097/QAD.0b013e3280ef6acd PubMedCrossRefGoogle Scholar
  40. Messier C, Mourre C, Bontempi B, Sif J, Lazdunski M, Destrade C (1991) Effect of apamin, a toxin that inhibits Ca(2+)-dependent K+ channels, on learning and memory processes. Brain Res 551:322–326. doi:10.1016/0006-8993(91)90950-Z PubMedCrossRefGoogle Scholar
  41. Nath A (1999) Pathobiology of human immunodeficiency virus dementia. Semin Neurol 19:113–127. doi:10.1055/s-2008-1040830 PubMedCrossRefGoogle Scholar
  42. Neuenburg JK, Brodt HR, Herndier BG, Bickel M, Bacchetti P, Price RW, Grant RM, Schlote W (2002) HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 31:171–177PubMedGoogle Scholar
  43. Parsons TD, Braaten AJ, Hall CD, Robertson KR (2006) Better quality of life with neuropsychological improvement on HAART. Health Qual Life Outcomes 4:11. doi:10.1186/1477-7525-4-11 PubMedCrossRefGoogle Scholar
  44. Persidsky Y, Gendelman HE (1997) Development of laboratory and animal model systems for HIV-1 encephalitis and its associated dementia. J Leukoc Biol 62:100–106PubMedGoogle Scholar
  45. Persidsky Y, Limoges J, McComb R, Bock P, Baldwin T, Tyor W, Patil A, Nottet H, Epstein L, Gelbard H, Flanagan E, Reinhard J, Pirruccello S, Gendelman H (1996) Human immunodeficiency virus encephalitis in SCID mice. Am J Pathol 149:1027–1053PubMedGoogle Scholar
  46. Petito CK, Roberts B (1995) Evidence of apoptotic cell death in HIV encephalitis. Am J Pathol 146:1121–1130PubMedGoogle Scholar
  47. Qiu MR, Campbell TJ, Breit SN (2002) A potassium ion channel is involved in cytokine production by activated human macrophages. Clin Exp Immunol 130:67–74. doi:10.1046/j.1365-2249.2002.01965.x PubMedCrossRefGoogle Scholar
  48. Reike F, de Warland R, Ruyter van Steveninck R, Bialek W (1997) Spikes: exploring the neural code. MIT, Cambridge, MAGoogle Scholar
  49. Remillard CV, Yuan JX (2004) Activation of K+ channels: an essential pathway in programmed cell death. Am J Physiol Lung Cell Mol Physiol 286:L49–L67. doi:10.1152/ajplung.00041.2003 PubMedCrossRefGoogle Scholar
  50. Rus H, Pardo CA, Hu L, Darrah E, Cudrici C, Niculescu T, Niculescu F, Mullen KM, Allie R, Guo L, Wulff H, Beeton C, Judge SI, Kerr DA, Knaus HG, Chandy KG, Calabresi PA (2005) The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A 102:11094–11099. doi:10.1073/pnas.0501770102 PubMedCrossRefGoogle Scholar
  51. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, Becker JT, Cohen B, McArthur JC (2001) HIV-associated neurologic disease incidence changes: multicenter AIDS Cohort Study, 1990–1998. Neurology 56:257–260PubMedGoogle Scholar
  52. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L (2002) HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 8:136–142. doi:10.1080/13550280290101094 PubMedCrossRefGoogle Scholar
  53. Sacktor N, Nakasujja N, Skolasky R, Robertson K, Wong M, Musisi S, Ronald A, Katabira E (2006) Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa. Neurology 67:311–314. doi:10.1212/01.wnl.0000225183.74521.72 PubMedCrossRefGoogle Scholar
  54. Sas AR, Bimonte-Nelson HA, Tyor WR (2007) Cognitive dysfunction in HIV encephalitic SCID mice correlates with levels of interferon-alpha in the brain. AIDS 21:2151–2159. doi:10.1097/QAD.0b013e3282f08c2f PubMedCrossRefGoogle Scholar
  55. Solntseva EI, Bukanova Iu V, Skrebitskii VG (2003) [Memory and potassium channels]. Usp Fiziol Nauk 34:16–25PubMedGoogle Scholar
  56. Stefoski D, Davis FA, Faut M, Schauf CL (1987) 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 21:71–77. doi:10.1002/ana.410210113 PubMedCrossRefGoogle Scholar
  57. Tozzi V, Balestra P, Galgani S, Narciso P, Ferri F, Sebastiani G, D'Amato C, Affricano C, Pigorini F, Pau FM, De Felici A, Benedetto A (1999) Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS 13:1889–1897. doi:10.1097/00002030-199910010-00011 PubMedCrossRefGoogle Scholar
  58. Vicente R, Escalada A, Coma M, Fuster G, Sanchez-Tillo E, Lopez-Iglesias C, Soler C, Solsona C, Celada A, Felipe A (2003) Differential voltage-dependent K+ channel responses during proliferation and activation in macrophages. J Biol Chem 278:46307–46320. doi:10.1074/jbc.M304388200 PubMedCrossRefGoogle Scholar
  59. Wiley CA, Achim C (1994) Human immunodeficiency virus encephalitis is the pathological correlate of dementia in acquired immunodeficiency syndrome. Ann Neurol 36:673–676. doi:10.1002/ana.410360422 published erratum appears in Ann Neurol 1995 Jan;37(1):140PubMedCrossRefGoogle Scholar
  60. Xiong H, Zheng J, Thylin M, Gendelman HE (1999) Unraveling the mechanisms of neurotoxicity in HIV type 1-associated dementia: inhibition of neuronal synaptic transmission by macrophage secretory products. AIDS Res Hum Retroviruses 15:57–63. doi:10.1089/088922299311718 PubMedCrossRefGoogle Scholar
  61. Zakharenko SS, Patterson SL, Dragatsis I, Zeitlin SO, Siegelbaum SA, Kandel ER, Morozov A (2003) Presynaptic BDNF required for a presynaptic but not postsynaptic component of LTP at hippocampal CA1-CA3 synapses. Neuron 39:975–990. doi:10.1016/S0896-6273(03)00543-9 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • James P. Keblesh
    • 1
    • 2
    • 3
  • Huanyu Dou
    • 2
    • 3
  • Howard E. Gendelman
    • 2
    • 3
  • Huangui Xiong
    • 1
    • 2
    • 3
  1. 1.Neurophysiology LaboratoryUniversity of Nebraska Medical CenterOmahaUSA
  2. 2.Center for Neurovirology and Neurodegenerative DisordersUniversity of Nebraska Medical CenterOmahaUSA
  3. 3.Department of Pharmacology and Experimental NeuroscienceUniversity of Nebraska Medical CenterOmahaUSA

Personalised recommendations